Literature DB >> 2366213

Social competence in schizophrenia: premorbid adjustment, social skill, and domains of functioning.

K T Mueser1, A S Bellack, R L Morrison, J T Wixted.   

Abstract

The relations between premorbid adjustment, social skill, and domains of functioning (symptoms, social adjustment) were examined in a group of 107 schizophrenic, schizoaffective, and affective disorder patients. Premorbid sexual adjustment was moderately correlated with social skill in the schizophrenic and schizoaffective patients. Schizophrenic patients had the lowest premorbid adjustment and social skill, followed by schizoaffectives, and then affective patients. Within the schizophrenic group, social skill was significantly related to both current social adjustment and negative symptoms, but not positive symptoms. Similar but weaker effects were found for premorbid adjustment. The results suggest that deficits in social skill are correlated with poor premorbid and morbid social adjustment of schizophrenics.

Entities:  

Mesh:

Year:  1990        PMID: 2366213     DOI: 10.1016/0022-3956(90)90024-k

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  19 in total

Review 1.  Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions.

Authors:  Deanna M Barch; Erin C Dowd
Journal:  Schizophr Bull       Date:  2010-06-21       Impact factor: 9.306

2.  Association between psychopathology and problems of psychosocial functioning in the long-term outcome of patients diagnosed with schizophrenic, schizoaffective and affective disorders.

Authors:  Ronald Bottlender; Anton Strauss; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06-22       Impact factor: 5.270

3.  Impact of untreated psychosis on quality of life in patients with first-episode schizophrenia.

Authors:  C W Law; Eric Y H Chen; Eric F C Cheung; Raymond C K Chan; Josephine G W S Wong; Cindy L K Lam; K F Leung; Molly S M Lo
Journal:  Qual Life Res       Date:  2005-10       Impact factor: 4.147

4.  A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia.

Authors:  Dawn I Velligan; David Roberts; Jim Mintz; Natalie Maples; Xueying Li; Elisa Medellin; Matt Brown
Journal:  Schizophr Res       Date:  2015-05-01       Impact factor: 4.939

Review 5.  The stigma of severe mental illness: some potential solutions for a recalcitrant problem.

Authors:  D L Penn; J Martin
Journal:  Psychiatr Q       Date:  1998

6.  Motivation deficits and use of alcohol and illicit drugs among individuals with schizophrenia.

Authors:  Amber L Bahorik; Catherine G Greeno; Gerald Cochran; Jack R Cornelius; Shaun M Eack
Journal:  Psychiatry Res       Date:  2017-04-05       Impact factor: 3.222

7.  Assessment of Lifespan Functioning Attainment (ALFA) scale: A quantitative interview for self-reported current and functional decline in schizophrenia.

Authors:  Jamie Joseph; William S Kremen; Stephen J Glatt; Carol E Franz; Sharon D Chandler; Xiaohua Liu; Barbara K Johnson; Ming T Tsuang; Elizabeth W Twamley
Journal:  J Psychiatr Res       Date:  2015-04-11       Impact factor: 4.791

8.  Assessing Social Affiliative Behavior: A Comparison of in Vivo and Video Tasks.

Authors:  Cristina P Garcia; Lauren T Catalano; Kristen R Dwyer; Julie M McCarthy; Melanie E Bennett; Jack J Blanchard
Journal:  Behav Ther       Date:  2018-03-19

9.  Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia.

Authors:  Jack J Blanchard; Ann M Kring; William P Horan; Raquel Gur
Journal:  Schizophr Bull       Date:  2010-09-22       Impact factor: 9.306

10.  Social affiliation and negative symptoms in schizophrenia: Examining the role of behavioral skills and subjective responding.

Authors:  Jack J Blanchard; Stephanie G Park; Lauren T Catalano; Melanie E Bennett
Journal:  Schizophr Res       Date:  2015-07-31       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.